Ten-year outcomes in a population-based cohort of node-negative, lymphatic, and vascular invasion-negative early breast cancers without adjuvant systemic therapies

Journal of Clinical Oncology

Volumn 22, Issue 9, 2004, Pages 1630-1637

  Chia, Stephen K ^a   Speers, Caroline H ^a   Bryce, Cicely J ^a   Hayes, Malcolm M ^a   Olivotto, Ivo A ^a  

^a BRITISH COLUMBIA CANCER AGENCY   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

ADJUVANT THERAPY; BREAST CANCER; CANCER GRADING; CANCER INVASION; CANCER MORTALITY; CANCER RELAPSE; CANCER SURVIVAL; FOLLOW UP; HUMAN; KAPLAN MEIER METHOD; LYMPH NODE METASTASIS; POPULATION RESEARCH; PRIORITY JOURNAL; REVIEW; SYSTEMIC THERAPY; TREATMENT OUTCOME; TUMOR VOLUME; ADJUVANT CHEMOTHERAPY; ADULT; AGED; ARTICLE; BREAST TUMOR; CANCER STAGING; COHORT ANALYSIS; DISEASE FREE SURVIVAL; FACTUAL DATABASE; FEMALE; MIDDLE AGED; PATHOLOGY; PROGNOSIS; REGISTER; STATISTICS; TUMOR RECURRENCE;

ADULT; AGED; AGED, 80 AND OVER; BREAST NEOPLASMS; CHEMOTHERAPY, ADJUVANT; COHORT STUDIES; DATABASES, FACTUAL; DISEASE-FREE SURVIVAL; FEMALE; HUMANS; MIDDLE AGED; NEOPLASM RECURRENCE, LOCAL; NEOPLASM STAGING; PROGNOSIS; REGISTRIES;

EID: 2442684453     PISSN: 0732183X     EISSN: None     Source Type: Journal    
DOI: 10.1200/JCO.2004.09.070     Document Type: Review

References (26)

1. Miller BA, Feuer EJ, Hankey BF: Recent incidence trends for breast cancer in females and the relevance of early detection: An update. CA Cancer J Clin 43:27-41, 1993
2. Fitzgibbons PL, Page DL, Weaver D, et al: Prognostic factors in breast cancer: College of American Pathologists Consensus Statement 1999. Arch Pathol Lab Med 124966-978, 2000
3. Goldhirsch A, glick JH, Gelber RD. et al: Meeting highlights: International consensus panel on the treatment of primary breast cancer. J Clin Oncol 19:3817-3827, 2001
4. National Institutes of Health Consensus Development Panel: National Institutes of Health consensus development conference statement-Adjuvant therapy for breast cancer. J Natl Cancer Inst 93:979-989, 2001
5. National Comprehensive Cancer Network: Breast cancer treatment guidelines for physicians. http://www.nccn.org
6. Early Breast Cancer Trialists' Collaborative Group. Polychemotherapy for early breast cancer: An overview of the randomized trials. Lancet 352:930-942, 1998
7. Early Breast Cancer Trialists' Collaborative Group. Tamoxifen for early breast cancer. Lancet 351:1451-1467, 1998
8. Lee AK, DeLellis RA, Silverman ML, et al: Prognostic significance of peritumoral lymphatic and blood vessel invasion in node negative carcinoma of the breast. J Clin Oncol 8:1457-1465, 1990
9. Clayton F: Pathologic correlates of survival in 378 lymph node negative infiltrating ductal breast carcinomas: Mitotic count is the best single predictor. Cancer 68:1309-1317, 1991
10. Clemente CG, Boracchi P, Andreola S, et al: Peritumoral lymphatic invasion in patients with node negative mammary duct carcinoma. Cancer 69:1396-1403, 1992
11. Elston CW, Ellis IO: Pathological prognostic factors in breast cancer: The value of histological grade in breast cancer: Experience from a large study with long-term follow-up. Histopathology 19:403-410, 1991
12. Hahnel R, Woodings T, Vivian AB: Prognostic value of estrogen receptors in primary breast cancer. Cancer 44:671-675, 1979
13. Aamdal S, Bormer O, Jorgensen O, et al: Estrogen receptors and long term prognosis in breast cancer. Cancer 53:2525-2529, 1984
14. Hilsenbeck SG, Ravdin P, de Moor CA, et al: Time-dependence of hazard ratios for prognostic factors in primary breast cancer. Breast Cancer Res Treat 52:227-237, 1998
15. Carter CL, Allen C, Henson DE: Relation of tumors size, lymph node status and survival in 24,740 breast cancer cases. Cancer 63:181-187, 1989
16. 0) breast carcinoma: A study of 644 patients with median follow-up of 18 years. J Clin Oncol 7:1239-1251, 1989
17. Rosen PP, Groshen S, Kinne DW, et al: Factors influencing prognosis in node negative breast carcinoma: Analysis of 767 T1N0M0/T2N0M0 patients with long term follow-up. J Clin Oncol 11:2090-2100, 1993
18. Tabar L, Fagerberg G, Day NE, et al: Breast cancer treatment and natural history: New insights from results of screening. Lancet 339: 412-414, 1992
19. Smart CR, Hartmann WH, Beahrs OH, et al: Insights into breast cancer screening of younger women. Cancer 72:1449-1456, 1993
20. Ravdin PM, Siminoff LA, Harvey JA: Survey of breast cancer patients concerning their knowledge and expectations of adjuvant therapy. J Clin Oncol 16:515-521, 1998
21. Loprinzi CL, Thome SD: Understanding the utility of adjuvant systemic therapy for primary breast cancer. J Clin Oncol 19:972-979, 2001
22. Ravdin PM, Siminoff LA, Davis GJ, et al: Computer program to assist in making decisions about adjuvant therapy for women with early breast cancer. J Clin Oncol 19:980-991, 2001
23. Olivotto IA, Mates D, Kan L, et al: Prognosis, treatment and recurrence of breast cancer for women attending or not attending the Screening Mammography Program of British Columbia. Breast Cancer Res Treat 54:73-81, 1999
24. Olivotto IA, Coldman AJ, Hislop TG. et al: Compliance with practice guidelines for node-negative breast cancer. J Clin Oncol 15:216-222, 1997
25. Sawka C, Olivotto IA, Coldman A, et al: The association between population-based treatment guidelines and adjuvant therapy for node-negative breast cancer. Br J Cancer 75:1534-1542, 1997
26. van't Veer LJ, Dal H, and van de Vijver MJ, et al: Gene expression profiling predicts clinical outcome of breast cancer. Nature 415:530-536, 2002